Biomarkers of insulin sensitivity and insulin resistance: Past, present and future (Q35652813)

9 August 2017

1 reference

title

Biomarkers of insulin sensitivity and insulin resistance: Past, present and future (English)

1 reference

9 August 2017

0 references

1 reference

1 reference

Se Eun Park

1

1 reference

9 August 2017

Cheol-Young Park

series ordinal

2

1 reference

9 August 2017

Gary Sweeney

series ordinal

3

1 reference

9 August 2017

publication date

4 June 2015

1 reference

Critical Reviews in Clinical Laboratory Sciences

9 August 2017

published in

1 reference

9 August 2017

volume

52

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

180-190

1 reference

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Defining insulin resistance from hyperinsulinemic-euglycemic clamps

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Biomarkers and immune-modulating therapies for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipokines - removing road blocks to obesity and diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Muscles, exercise and obesity: skeletal muscle as a secretory organ

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The role of hepatokines in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipokines and insulin action: A sensitive issue

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Post-translational modifications of adiponectin: mechanisms and functional implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin action: a combination of endocrine and autocrine/paracrine effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin, driver or passenger on the road to insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin signaling in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin receptor as a key player in healthy longevity and obesity-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin and its receptors: implications for obesity-associated diseases and longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Therapeutic perspectives for adiponectin: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people: the Korean Longitudinal Study on Health and Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum retinol-binding protein 4 as a marker for cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

RBP4: a controversial adipokine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Next-generation biomarkers for detecting kidney toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin: a potential endocrine link between obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Towards an integrative approach to understanding the role of chemerin in human health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Chemerin is a novel adipokine associated with obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

A-FABP--a biomarker associated with the metabolic syndrome and/or an indicator of weight change?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipocyte fatty acid-binding protein in obese children before and after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum FGF-21 levels in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Inventing new medicines: The FGF21 story

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fetuin-A and incident diabetes mellitus in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum fetuin-A is an independent marker of insulin resistance in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Fetuin-A induces cytokine expression and suppresses adiponectin production

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adipo-myokines: two sides of the same coin--mediators of inflammation and mediators of exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

IL-6 selectively stimulates fat metabolism in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Enhanced skeletal muscle for effective glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The central role of myostatin in skeletal muscle and whole body homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Increased secretion and expression of myostatin in skeletal muscle from extremely obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Role of myostatin in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Myostatin decreases with aerobic exercise and associates with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Investigation of myostatin serum levels before and after a 6-month lifestyle intervention program in obese children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Irisin as a muscle-derived hormone stimulating thermogenesis--a critical update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Is irisin a human exercise gene?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Circulating irisin in relation to insulin resistance and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Serum irisin levels in new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Systems biology: Metabonomics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Application of combined omics platforms to accelerate biomedical discovery in diabesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Human serum proteome analysis: new source of markers in metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Metabolomic profiling as a useful tool for diagnosis and treatment of chronic disease: focus on obesity, diabetes and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Application of metabolomics to diagnosis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Metabolomics reveals broad-scale metabolic perturbations in hyperglycemic mothers during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Adiponectin corrects high-fat diet-induced disturbances in muscle metabolomic profile and whole-body glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The genetics of type 2 diabetes: what have we learned from GWAS?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

A combined epidemiologic and metabolomic approach improves CKD prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

An atlas of genetic influences on human blood metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Assessing the human gut microbiota in metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Gut microbiome, obesity, and metabolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The Gut Microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Introducing GUt low-density array (GULDA): a validated approach for qPCR-based intestinal microbial community analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

The human gut chip "HuGChip", an explorative phylogenetic microarray for determining gut microbiome diversity at family level

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Modulating the human gut microbiome as an emerging therapeutic paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

Metabolic and molecular basis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408363.2015.1023429

10.3109/10408363.2015.1023429

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference